CoronaryAtlas logo
CoronaryAtlas
creatine
Pathway / Myocardial injury (shared endpoint)

creatine

metabolite

Creatine dysregulation reflects impaired myocardial energetics in acute coronary syndrome and recovery, marking cardiomyocyte ischemic injury and metabolic restoration.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleMyocardial high-energy phosphate metabolism; downregulated in ACS; relates to cardiac energy depletion and recovery phase.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
57
A — assay feasibility
42
E — evidence strength
—
T1DI (composite)
0
Specificity differential (R−C)-42.1
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 1
Coverage: 7/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 10 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(3)